Charter

Institutional Biosafety Committee
University of Maryland
June 1996
Revised May 2006
Approved May 2006

Article I. Introduction

The Institutional Biosafety Committee (IBC) is a subcommittee of the Biological and Chemical Hygiene (BACH) Committee of the University of Maryland. Its existence is mandated in Section IV-B-1-b of the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), April 2002, which states that "Each institution conducting or sponsoring recombinant DNA research which is covered by the NIH Guidelines is responsible for ensuring that the research is conducted in full conformity with the provisions of the NIH Guidelines. In order to fulfill this responsibility, the institution shall: ... establish an Institutional Biosafety Committee..." The policy of the committee is to work cooperatively with researchers, faculty and staff while assuring compliance with the NIH Guidelines.

Article II. Responsibilities

The responsibilities of the IBC are derived from those listed in the NIH Guidelines:

Reviewing recombinant DNA research conducted at or sponsored by the institution for compliance with the NIH Guidelines and approving those research projects that are found to conform with the NIH Guidelines.
1. Experiments that require IBC approval before initiation - Section III-D. The Biosafety Officer (BSO) will review the registration and make the determination that it requires IBC approval before initiation. The IBC will review all registrations in this category at a convened meeting.
2. Experiments that require IBC notice simultaneous with initiation - Section III-E.. The BSO will review the registration and make the determination that it requires notification of the IBC, and will inform the PI that the registration has been reviewed and the containment level that is required. The BSO will submit the registration at the next IBC meeting for review and comment. At this time, the committee may change the conditions of the approval if it feels this to be necessary.
3. Experiments that are exempt from the NIH Guidelines - Section III-F. The BSO will review the registration and make the determination that it is exempt, and will inform the Principal Investigator (PI) that the registration has been reviewed and the containment level that should be used. The IBC will not review exempt experiments.
Notifying the Principal Investigator of the results of the IBC's review and approval.
Lowering containment levels for certain experiments as specified in Section III-D-2-a of the NIH Guidelines.
Setting containment levels that are not set by the NIH Guidelines.
Periodically reviewing recombinant DNA research conducted at the institution to ensure compliance with the NIH Guidelines.
Adopting emergency plans covering accidental spills and personnel contamination resulting from recombinant DNA research.
Reporting any significant problems with or violations of the NIH Guidelines and any significant research-related accidents or illnesses to the appropriate institutional official and NIH Office of Biotechnology Activities (OBA) within 30 days, unless the IBC determines that a report has already been filed by the Principal Investigator.
Performing such other functions as may be delegated to the IBC, including review of non-recombinant human pathogens and Select Agents and Toxins according to the current edition of the NIH/CDC publication Biosafety in Microbiological and Biomedical Laboratories.
1. Biosafety Level 2. The BSO will review registrations involving non-recombinant Risk Group 2 human pathogens and notify the PI of the containment level required.
2. Biosafety Level 3. The IBC will review and assign containment for all registrations involving non-recombinant Risk Group 3 human pathogens at a convened meeting.
3. Select Agents and Toxins. The IBC will review and approve all registrations of Select Agents and Toxins at a convened meeting.

The IBC may not authorize initiation of experiments that are not explicitly covered by the NIH Guidelines until NIH (with the advice of the Recombinant DNA Advisory Committee when required) establishes the containment requirement.

Article III. Membership

The IBC is comprised of no fewer than five members so selected that they collectively have experience and expertise in recombinant DNA technology. At least two members shall not be affiliated with the institution (apart from their membership on the IBC), and at least one member shall be a representative of the laboratory technical staff.
Members are recommended by the IBC Chair to the Vice President for Research, who makes the appointment. The term of appointment is 3 years, which is renewable.
The IBC Chair is appointed by the Vice President for Research.
IBC members need not be members of the BACH Committee.

Article IV. Management

The IBC shall meet as needed, but at least once per year.
The review of all registrations shall take place at convened meetings at which a majority of the members of the IBC are present, including at least one community member.
A convened meeting shall be conducted in person, or via conference call.
The BSO shall be a member of the IBC, shall serve as Executive Secretary, and shall be responsible for preparation of the meeting minutes.
The Biosafety Manual for University of Maryland is incorporated into this charter by reference.
The BSO shall assign an approval number to each registration, which may be used by the PI when submitting subsequent grant proposals that use the same recombinant DNA systems. A separate registration will not be needed for each grant proposal unless a different host/vector/insert system will be used.

Revised 01/08/00
Revised and approved 05/04/06

We would greatly appreciate your feedback about this site.